triazoles has been researched along with efavirenz in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 20 (57.14) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
| Authors | Studies |
|---|---|
| Girardet, JL; Hamatake, RK; Hong, Z; Koh, YH; Shim, JH; Xu, W; Yeh, LT; Zhang, Z | 1 |
| Foster, G; Gutierrez, MJ; LaBadie, RR; Liu, P; Sharma, A | 1 |
| Crownover, P; Damle, B; Glue, P; LaBadie, R | 1 |
| Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S | 1 |
| Sax, PE | 1 |
| Carbonara, S; Ciracì, E; Cusato, M; Heichen, M; Monno, L; Regazzi, M; Stano, F; Villani, P | 1 |
| Krishna, G; Ma, L; Martinho, M; McLeod, J; Moton, A; Seiberling, M | 1 |
| Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
| Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
| Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H | 1 |
| Chapman, D; Dong, WW; Harrigan, PR; Heera, J; James, I; Jensen, MA; Knapp, DJ; Lewis, M; Mo, T; Portsmouth, S; Swenson, LC; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Desta, Z; Guo, Y; Ogburn, ET; Xu, C | 1 |
| Colby-Germinario, SP; Donahue, DA; Kramer, VG; Oliveira, M; Schader, SM; Singhroy, DN; Sloan, RD; Tressler, R; Wainberg, MA | 1 |
| Lu, HZ; Shen, YZ; Wang, ZY | 1 |
| Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Nelson, M; Newell, S; Rockwood, N; Waters, L | 1 |
| Achhra, AC; Boyd, MA; Cooper, DA; Kelleher, AD; Law, MG; Matthews, GV | 1 |
| Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S | 1 |
| Back, D; Davies, G; Khoo, S; Owen, A; Schipani, A; Siccardi, M | 1 |
| Albanese, A; Asmuth, DM; Chun, TW; Deeks, SG; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Moreno, S; Pollard, RB; Sainz, T; Serrano-Villar, S; Siewe, B; Sinclair, E; Somasunderam, A; Troia-Cancio, P; Utay, NS; Wook-Chun, T; Yotter, T | 1 |
| Blair, W; Feng, M; Grobler, J; Hazuda, DJ; Lai, MT; Miller, MD; Sachs, NA; Xu, M | 1 |
| Auger, P; Di Spirito, M; Fan, L; Iwamoto, M; Khalilieh, SG; Lai, MT; Liu, R; Sanchez, RI; Triantafyllou, I; Yee, KL | 1 |
| Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL | 1 |
| Asmuth, DM; Chun, TW; Garcia, JC; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Pollard, RB; Sainz, T; Serrano-Villar, S; Thompson, CG; Troia-Cancio, P; Utay, NS | 1 |
| Baptista, MS; Bastos, MM; Boechat, N; Cafffarena, ER; Costa, CCP; da Silva, FC; Hoelz, LVB; Marttorelli, A; Souza, TML | 1 |
| Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
| Anderson, MS; Fan, L; Iwamoto, M; Khalilieh, SG; Laethem, T; Rasmussen, S; Sanchez, RI; Sura, M; van Bortel, L; van Lancker, G; Yee, KL | 1 |
| Arastéh, K; Dretler, R; Frobose, C; Gatell, JM; Hagins, DP; Harvey, C; Hoffmann, C; Hwang, C; Kumar, S; Morales-Ramirez, JO; Osiyemi, O; Plettenberg, A; Portilla, J; Raffi, F; Rodgers, A; Rugina, S; Smith, DE; Teppler, H; Thompson, M; Wan, H; Xu, X | 1 |
| Asante-Appiah, E; Feng, M; Graham, D; Hazuda, DJ; Hwang, C; Kumar, S; Lai, MT; Martin, EA; Ngo, W; Sklar, P | 1 |
| Cabalu, TD; Dreyer, D; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Kuo, Y; Liu, Y; McClain, S; Sanchez, RI; Stoch, SA; Triantafyllou, I; Wenning, L; Yee, KL | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
3 review(s) available for triazoles and efavirenz
| Article | Year |
|---|---|
[Maraviroc efficacy in clinical studies on the development of the molecule].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2008 |
Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole | 2014 |
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; In Vitro Techniques; Pyridones; Rilpivirine; Triazoles | 2020 |
14 trial(s) available for triazoles and efavirenz
| Article | Year |
|---|---|
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
Topics: Adolescent; Adult; Age Factors; Alkynes; Antifungal Agents; Area Under Curve; Benzoxazines; Body Weight; Capsules; Creatine Kinase; Cyclopropanes; Drug Interactions; Heart Block; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pyrimidines; Reverse Transcriptase Inhibitors; Rhabdomyolysis; Tablets; Triazoles; Voriconazole | 2008 |
Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Benzoxazines; Cross-Over Studies; Cyclopropanes; Drug Interactions; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Triazoles | 2009 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
Topics: Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Reverse Transcriptase Inhibitors; Triazoles; Viral Load | 2010 |
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; Female; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Failure; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2011 |
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2014 |
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Cyclopropanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Mucosal; Lymphocyte Activation; Male; Maraviroc; Pilot Projects; Raltegravir Potassium; T-Lymphocyte Subsets; Triazoles | 2016 |
Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; Headache; Healthy Volunteers; Humans; Male; Middle Aged; Pyridones; Triazoles | 2017 |
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; DNA, Viral; Duodenum; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Maraviroc; Raltegravir Potassium; Rectum; RNA, Viral; Triazoles | 2017 |
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2019 |
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
Topics: Adult; Alkynes; Benzoxazines; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Biological; Pyridones; Reverse Transcriptase Inhibitors; Rifabutin; Rifampin; Triazoles; Young Adult | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
18 other study(ies) available for triazoles and efavirenz
| Article | Year |
|---|---|
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Dogs; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Triazoles | 2007 |
Anti-HIV agents. New drugs, new hope, old lessons.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Lipodystrophy; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles; Viral Load | 2007 |
Maraviroc reduces viral load in naive patients at 48 weeks.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Load | 2007 |
Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers.
Topics: Adult; Alkynes; Antifungal Agents; Benzoxazines; Body Weight; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Epidemiologic Methods; Humans; Male; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Voriconazole | 2008 |
Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
Topics: Alkynes; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; HIV Infections; Humans; Maraviroc; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Humans; Liver Cirrhosis; Male; Meningitis, Cryptococcal; Pyrimidines; Triazoles; Voriconazole | 2009 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
Topics: Alkynes; Alleles; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biotransformation; Bupropion; Catalysis; Clopidogrel; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochromes b5; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyrimidines; Substrate Specificity; Ticlopidine; Triazoles; Voriconazole | 2012 |
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzylamines; Cell Line; Cyclams; Cyclohexanes; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load; Virus Internalization | 2012 |
Penicillium marneffei chylous ascites in acquired immune deficiency syndrome: a case report.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Alkynes; Amphotericin B; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Chylous Ascites; Cyclopropanes; Diagnosis, Differential; Humans; Male; Middle Aged; Mycoses; Penicillium; Pyrimidines; Sepsis; Triazoles; Voriconazole | 2012 |
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Cyclohexanes; Cyclopropanes; Drug Administration Schedule; Drug Substitution; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Viral Load | 2015 |
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; Dideoxynucleosides; Feasibility Studies; Female; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Ritonavir; Tenofovir; Triazoles | 2014 |
Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials as Topic; Computer Simulation; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Fusion Inhibitors; Humans; In Vitro Techniques; Male; Maraviroc; Middle Aged; Models, Biological; Nevirapine; Reverse Transcriptase Inhibitors; Triazoles; Young Adult | 2015 |
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Viral; Gene Expression; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Pyridones; Rilpivirine; Triazoles | 2016 |
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine | 2017 |
New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles | 2018 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult | 2019 |